The Medical Device Innovation Consortium (MDIC) Announces New Chair-Elect for Board of Directors

ARLINGTON, Va.–(BUSINESS WIRE)–#MDIC–The Medical Device Innovation Consortium (MDIC) today announced that its board of directors has elected Jijo James, Chief Medical Officer of Johnson & Johnson Medical Devices Companies, as the new chair-elect of the MDIC board.

James has been on the MDIC Board of Directors since 2017 and a member of the MDIC Executive Committee since 2018. He also chairs MDIC’s Clinical Science and Medical Officer forum, a group of senior scientific and medical executives from medical device and diagnostics companies, government, and non-profit organizations, that provides advice to MDIC’s Board on issues regarding clinical and regulatory science and patient safety to maximize clinical and medical value. As chair-elect of the board, James is next in line to become board chair in June 2021, succeeding current chair Nadim Yared, CEO of CVRx.

“Jijo has been a visionary advisor for MDIC and for me over the years. I look forward to further engaging his wisdom and vision for the next phase of MDIC, leveraging his knowledge as a physician and as a healthcare leader,” said MDIC President and CEO Pamela Goldberg.

As Chief Medical Officer for Johnson & Johnson Medical Devices Companies, James is responsible for overseeing patient monitoring and safety surveillance practices across the company’s Medical Devices product portfolio. James is a member of the Johnson & Johnson Office of the Chief Medical Officer Senior Leadership team and Medical Devices R&D Leadership team. Prior to joining Johnson & Johnson, James spent six years at Pfizer, Inc. where he held roles of increasing responsibility with safety and regulatory focuses both in the United States and abroad. He has extensive global experience working in emerging markets and with payers, providers and life sciences companies in a number of collaborative programs.

“This year has reminded us how critical medical device and diagnostic innovation is to the communities in which we live and work. I look forward to continuing the important work of MDIC in promoting patient access to innovative medical technologies while prioritizing safety and efficacy,” said James.

James began his medical career working directly with patients as a primary care physician in both urban and rural community settings. Having received his medical degree from St. John’s Medical College in India, he later earned a Master of Public Health degree in Population and Family studies from the Joseph L. Mailman School of Public Health, Columbia University, New York, NY.

About the Medical Device Innovation Consortium

Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate the development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives aim to improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market. For more information, visit http://www.mdic.org.

Contacts

Taylor Jackson
tjackson@mdic.org
+1 202.510.9391

Staff

Recent Posts

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today…

57 mins ago

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY )…

57 mins ago

Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext…

57 mins ago

Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024

LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally…

10 hours ago

Free Dementia Training in Alabama

Bring Dementia Education at No Cost to Your Skilled Nursing HomeTUSCALOOSA, AL / ACCESSWIRE /…

10 hours ago

Accuryn Medical Announces Maclean Health FSS Contract Award

Accuryn Monitor Now Included in Department of Veteran Affairs (VA) Federal Supply Schedule (FSS)HAYWARD, CA…

13 hours ago